GSK CEO Confident Amid Anticipated US Tariffs, Eyes Growth in China

GSK's CEO Emma Walmsley expressed confidence in the company's ability to navigate anticipated tariffs on the pharmaceutical industry, emphasizing the U.S. market's critical role, which accounts for over half of GSK's operations. During a recent interview, she asserted that GSK is also excited about growth opportunities in China, despite ongoing geopolitical tensions. The company is focusing on restructuring its supply chain and establishing alternative sourcing to mitigate risks associated with U.S.-China trade relations. Walmsley's strategic approach aims to ensure stability in U.S. operations while capitalizing on China's growing market for infectious disease treatments. This dual focus not only safeguards GSK against geopolitical pressures but also bolsters investor confidence amid uncertain global trade dynamics. Overall, GSK is positioning itself to adapt to challenges while pursuing expansion in key markets.